Twist Bioscience Corp. Hits New 52-Week High at $66.84

Twist Bioscience Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 66.84 on May 27, 2026. This achievement marks a notable increase from its 52-week low of USD 23.50, reflecting a robust performance over the past year. In the last year, Twist Bioscience Corp. has demonstrated a performance increase of 28.31%, slightly outpacing the S&P 500's growth of 27.0%. The company's market capitalization stands at USD 2,760 million, positioning it firmly within the small-cap category. Despite its recent price surge, the company remains in a loss-making position, with a negative return on equity of -16.79%. Additionally, the stock has a price-to-book ratio of 6.05, indicating a premium valuation relative to its book value. With no dividend yield and a debt-to-equity ratio of -0.41, Twist Bioscience Corp. continues to navigate the competitive landscape of the biotechnology industry while achieving this notable price milestone.